Silverback Therapeutics (NASDAQ:SBTX) Trading Down 0.1% - Here's What Happened

Key Points

• Shares dipped 0.1% to $8.29 (intraday low $7.95) on heavy trading of 2,059,229 shares, a 509% increase versus the average session volume.
• Technically the stock sits below its 50-day ($8.50) and 200-day ($9.46) simple moving averages and has a market capitalization of about $298.9 million with a negative PE of -3.43.
• Silverback is a clinical-stage biotech developing its proprietary ImmunoTAC™ platform—antibody–TLR agonist conjugates designed to activate innate immunity in the tumor microenvironment, with multiple early‑phase programs underway.

Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report)'s share price traded down 0.1% during trading on Monday . The company traded as low as $7.95 and last traded at $8.29. 2,059,229 shares changed hands during mid-day trading, an increase of 509% from the average session volume of 337,931 shares. The stock had previously closed at $8.30.

Silverback Therapeutics Trading Down 0.1%

The firm's 50-day simple moving average is $8.50 and its two-hundred day simple moving average is $9.46. The stock has a market capitalization of $298.92 million, a PE ratio of -3.43 and a beta of 0.60.

About Silverback Therapeutics

Silverback Therapeutics, Inc NASDAQ: SBTX is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company's proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback's pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.